Department of Medicine, Division of Gastroenterology and Hepatology, Texas Tech University Health Science Center-Paul L. Foster School of Medicine, El Paso, TX, USA.
J Clin Transl Hepatol. 2014 Mar;2(1):45-52. doi: 10.14218/JCTH.2013.00021. Epub 2014 Mar 15.
Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver disease that often leads to the development of cirrhosis. Complications of PSC include pruritus, fatigue, vitamin deficiencies, metabolic bone disease, dominant biliary strictures, gallstones, and hepatobiliary malignancies, most commonly cholangiocarcinoma (CCA). Despite the presumed autoimmune etiology of PSC, a clear benefit from immunosuppressive agents has not yet been established, and their use is limited by their side effects. Endoscopy is required in evaluation of biliary strictures in PSC to rule out the possibility of CCA. Liver transplantation is currently the only life-extending therapy for patients with end-stage disease. However, disease recurrence can be a source of morbidity and mortality as transplanted patients survive longer. Further studies are needed to develop an optimal therapeutic strategy for patients with PSC to decrease the incidence of complications of the disease, to decrease the need for transplantation, and to extend life expectancy.
原发性硬化性胆管炎(PSC)是一种慢性进行性胆汁淤积性肝病,常导致肝硬化的发生。PSC 的并发症包括瘙痒、疲劳、维生素缺乏、代谢性骨病、主要胆管狭窄、胆结石和肝胆恶性肿瘤,最常见的是胆管癌(CCA)。尽管 PSC 的发病机制被认为是自身免疫性的,但免疫抑制剂的明确益处尚未得到证实,其使用受到其副作用的限制。在 PSC 中评估胆管狭窄时需要进行内镜检查,以排除 CCA 的可能性。肝移植是终末期疾病患者唯一可延长生命的治疗方法。然而,随着移植患者存活时间的延长,疾病复发可能成为发病率和死亡率的一个来源。需要进一步的研究来为 PSC 患者制定最佳的治疗策略,以降低疾病并发症的发生率,减少移植的需求,并延长预期寿命。